^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

Vumon (teniposide)

i
Other names: vm 26, VM-26, VM26
Company:
BMS
Drug class:
Topoisomerase II inhibitor
Related drugs:
4d
Teniposide + Bevacizumab: A Phase II Study on Efficacy and Safety in Recurrent Glioblastoma (ChiCTR2600115949)
P2, N=33, Not yet recruiting, Henan Cancer Hospital; Henan Cancer Hospital
New P2 trial
|
Avastin (bevacizumab) • Vumon (teniposide)
16d
STING activation by teniposide: a potential direct mechanism beyond cGAS stimulation. (PubMed, Front Immunol)
These findings suggest that Teniposide activates STING through a previously unrecognized, cGAS-independent mechanism, while retaining potential for canonical cGAS-STING stimulation. Our combined computational and experimental evidence supports repurposing Teniposide as a STING agonist, highlighting new therapeutic possibilities for innate immune stimulation.
Journal
|
STING (stimulator of interferon response cGAMP interactor 1) • CGAS (Cyclic GMP-AMP Synthase) • IFI16 (Interferon Gamma Inducible Protein 16) • IFNB1 (Interferon Beta 1)
|
Vumon (teniposide)
2ms
Post-line Treatment With Teniposide for c-Myc-driven Extensive-stage Small Cell Lung Cancer (clinicaltrials.gov)
P2, N=15, Recruiting, Shanghai Pulmonary Hospital, Shanghai, China | Not yet recruiting --> Recruiting | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Jul 2025 --> Jun 2026
Enrollment open • Trial completion date • Trial primary completion date
|
Vumon (teniposide)
3ms
Multimodal treatment with thiotepa, bevacizumab, teniposide, and tunlametinib in a patient with neurofibromatosis type 1-associated oligodendroglioma: a rare case report. (PubMed, Anticancer Drugs)
As of June 2025, the patient has achieved a CR with a progression-free survival of 9 months before experiencing disease recurrence. This rare case of NF1-associated oligodendroglioma was managed with thiotepa, bevacizumab, teniposide, and tunlametinib, highlighting the potential of MEK inhibition in NF1-related gliomas.
Journal
|
NF1 (Neurofibromin 1)
|
Avastin (bevacizumab) • Kolupin (tunlametinib) • Vumon (teniposide) • thiotepa
3ms
Teniposide combined with bevacizumab for the treatment of recurrent high-grade MGMT promoter unmethylated glioma: A single-center prospective study (ChiCTR2500108634)
P=N/A, N=20, Not yet recruiting, West China Hospital of Sichuan University; West China Hospital of Sichuan University
New trial
|
MGMT (6-O-methylguanine-DNA methyltransferase)
|
Avastin (bevacizumab) • Vumon (teniposide)
4ms
New P2/3 trial
|
Rituxan (rituximab) • Inokai (orelabrutinib) • dexamethasone • Vumon (teniposide)
5ms
Triggering mitotic catastrophe by podophyllotoxin induces apoptosis in oral squamous cell carcinoma. (PubMed, Arch Oral Biol)
This study provides compelling evidence supporting the potential therapeutic significance of inducing MC-mediated apoptosis in OSCC. The results underscore the role of PPT and its derivatives, such as etoposide and teniposide, in targeting rapidly dividing cancer cells through interference with mitotic progression, offering insights into novel therapeutic strategies for oral cancer.
Journal
|
CHEK2 (Checkpoint kinase 2) • BAX (BCL2-associated X protein) • ANXA5 (Annexin A5) • CCNB1 (Cyclin B1)
|
etoposide IV • Vumon (teniposide)
6ms
Teniposide Triggers DNA Repair Inhibition by Binding and Ubiquitination of Apurinic/Apyrimidinic Endonuclease 1 to Boost Oxidative DNA Damage for Lung Cancer Destruction. (PubMed, ACS Pharmacol Transl Sci)
In summary, these data make a strong argument for the notion that Ten/VM-26-mediated inhibition of APEX1 contributes to DNA damage and thereby achieves favorable antilung cancer effects, wherein Ten/VM-26 could down-regulate APEX1 by binding and ubiquitination. The current study presents a critical target and mechanism for Ten/VM-26-mediated antilung cancer therapy.
Journal
|
APEX1 (Apurinic/Apyrimidinic Endodeoxyribonuclease 1)
|
Vumon (teniposide)
6ms
New P4 trial
|
cisplatin • Vumon (teniposide)
6ms
New trial
|
Vumon (teniposide) • thiotepa • busulfan
7ms
Trial completion
|
CD20 (Membrane Spanning 4-Domains A1)
|
CD20 positive
|
Rituxan (rituximab) • cytarabine • carmustine • Vumon (teniposide)
10ms
Differences in transcriptome characteristics and drug repositioning of Alzheimer's disease according to sex. (PubMed, Neurobiol Dis)
The characteristics of the transcriptome in peripheral blood and single-cell transcriptome in the prefrontal cortex exhibit significant differences between male and female patients with AD, which providing a basis for future sex stratified treatment of AD.
Journal
|
BASP1 (Brain Abundant Membrane Attached Signal Protein 1)
|
Vumon (teniposide) • Synribo (omacetaxine mepesuccinate)